Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:26:31.213Z.
Calculation as of: 2026-10-06T18:26:31.213Z.
Quote observation: 2026-10-06T18:25:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a99f3f088f54f9f9c0225e5104dac3e52b54f392bb47ad8d1f9af79329b73e7d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$4.39B
EV/Sales Ratio
15.02x
TTM Avg
10.97x
3Y Avg
7.20x
5Y Avg
8.58x
Market Cap
$4.43B
EV/Sales Ratio
3.54x
TTM Avg
3.64x
3Y Avg
2.36x
5Y Avg
2.44x
Market Cap
$4.46B
EV/Sales Ratio
21.00x
TTM Avg
14.60x
3Y Avg
14.88x
5Y Avg
14.88x
Market Cap
$4.02B
EV/Sales Ratio
61.01x
TTM Avg
32.22x
3Y Avg
29.33x
5Y Avg
20.17x
Market Cap
$4.02B
EV/Sales Ratio
379.69x
TTM Avg
210.46x
3Y Avg
121.97x
5Y Avg
409.64x
Market Cap
$4.65B
EV/Sales Ratio
1.01x
TTM Avg
0.96x
3Y Avg
1.19x
5Y Avg
1.40x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edgewise Therapeutics, Inc. (EWTX) | $4.31B | N/A | N/A | N/A | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.39B | 15.02x | 10.97x | 7.20x | 8.58x |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.43B | 3.54x | 3.64x | 2.36x | 2.44x |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.46B | 21.00x | 14.60x | 14.88x | 14.88x |
| LivaNova PLC (LIVN)vs › | $4.14B | 2.70x | 2.59x | 2.49x | 2.81x |
| AbCellera Biologics Inc. (ABCL)vs › | $4.02B | 61.01x | 32.22x | 29.33x | 20.17x |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.02B | 379.69x | 210.46x | 121.97x | 409.64x |
| ICU Medical, Inc. (ICUI)vs › | $3.97B | 2.29x | 2.08x | 2.00x | 2.38x |
| Option Care Health, Inc. (OPCH)vs › | $4.65B | 1.01x | 0.96x | 1.19x | 1.40x |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.68B | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
